DMX 700
Alternative Names: DMX-700Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Dimerix Bioscience
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in Australia
- 24 Sep 2020 DMX 700 is available for licensing as of 24 Sep 2020. https://dimerix.com/partnering/
- 24 Sep 2020 Preclinical trials in Chronic obstructive pulmonary disease in Australia (unspecified route) before September 2020 (Dimerix Bioscience pipeline, September 2020)